1. Salerno F, Gerbes A, Gine`s P et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310–8.
2. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Практическое руководство. Под ред. З.Г.Апросиной, Н.А.Мухина. М.: Гэотар-Медицина, 1999.
3. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164–76.
4. Moreau R, Lebrec D. Review article: hepatorenal syndrome – definitions and diagnosis. Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 24–8.
5. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729–37.
6. Gines P, Guevara M, Arroyo V, Rod_s J. Hepatorenal syndrome. Lancet 2003; 362: 1819–27.
7. Arroyo V, Fernandez J, Gines P. Pathogenesis and Treatment of Hepatorenal Syndrome. Semin Liver Dis 2008; 28: 81–95.
8. Yeung E, Yong E, Wong F. Renal dysfunction in cirrhosis: diagnosis, treatment, and prevention. http://www.medscape.com/viewarticle/495166.
9. Пиманов С.И. Гепаторенальный синдром. Consilium Medicum 2005; 1 (Прил. Гастроэнтерология): с. 21–5.
10. Cardenas A. Hepatorenal Syndrome: A Dreaded Complication of End-Stage Liver Disease. Am J Gastroenterol 2005; 100: 460–7.
11. Moller S, Bendtsen F, Henriksen J. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol 2005; 40: 491–500.
12. Fernandez J, Escorsell A, Zabalza M et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006; 44: 1288–95.
13. Силивончик Н.Н. Цирроз печени. 2-е изд. Мн.: УП "Технопринт", 2001.
14. Sanyal Arun J. Hepatorenal syndrome. J Gastroenterol Hepatol 2002; 17: S248–52.
15. Gines P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 57–62.
16. Arroyo V. Review article: hepatorenal syndrome – how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 49–54.
17. Маммаев С.Н. Фульминантная печеночная недостаточность: критерии диагноза и лечения. Клин. персп. гастроэнтерол. гепатол. 2002; 1: 2–8.
18. Duvoux C, Zanditenas D, Hezode C et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374–80.
19. Sharma P, Kumar A, Sharma B, Sarin S. An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response. Am J Gastroenterol 2008; 103: 1689–97.
20. Solanki P, Chawla A, Garg R et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152–6.
21. Lebrec D. Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 65–7.
22. Angeli V. Review article: prognosis of hepatorenal syndrome – has it changed with current practice? Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 44–6.
23. Brinch K, Moller S, Bendtsen F et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003; 39: 24–31.

С.И.Пиманов